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Abstract
Beside its well described role in the central and peripheral nervous system 5-hydroxytryptamine (5-HT), commonly known as
serotonin, is also a potent immuno-modulator. Serotoninergic receptors (5-HTR) are expressed by a broad range of
inflammatory cell types, including dendritic cells (DCs). In this study, we aimed to further characterize the immuno-
biological properties of serotoninergic receptors on human monocyte-derived DCs. 5-HT was able to induce oriented
migration in immature but not in LPS-matured DCs via activation of 5-HTR1 and 5-HTR2 receptor subtypes. Accordingly, 5-
HT also increased migration of pulmonary DCs to draining lymph nodes in vivo. By binding to 5-HTR3, 5-HTR4 and 5-HTR7
receptors, 5-HT up-regulated production of the pro-inflammatory cytokine IL-6. Additionally, 5-HT influenced chemokine
release by human monocyte-derived DCs: production of the potent Th1 chemoattractant IP-10/CXCL10 was inhibited in
mature DCs, whereas CCL22/MDC secretion was up-regulated in both immature and mature DCs. Furthermore, DCs
matured in the presence of 5-HT switched to a high IL-10 and low IL-12p70 secreting phenotype. Consistently, 5-HT
favoured the outcome of a Th2 immune response both in vitro and in vivo. In summary, our study shows that 5-HT is a
potent regulator of human dendritic cell function, and that targeting serotoninergic receptors might be a promising
approach for the treatment of inflammatory disorders.
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Introduction
Outside the central nervous systems 5-hydroxytryptamine (5-
HT), commonly known as serotonin, is found mainly in platelets
and can be released during platelet aggregation. Additionally, it has
been shown that mast cells are also able to store and release 5-HT,
e.g. after cross-linking of membrane bound IgEs by allergens [1–3].
The wide variety of biological activities and the complexity of
pharmacologic activities mediated by 5-HT, are due to the
existence of different classes of serotoninergic receptors (5-HTR)
[4]: the 5-HTR1 subgroup consists of at least five subtypes namely
5-HTR1A, 5-HTR1B, 5-HTR1D, 5-HTR1E, and 5-HTR1F.5 -
HTR1A interacts with several G proteins, eliciting different
responses [5]. 5-HTR1B and 5-HTR1D are coupled to formation
of inositol phosphates through interaction with pertussis toxin–
sensitive Gi/o and pertussis toxin–insensitive Gq proteins [6]. The
G protein–coupled 5-HTR2 includes three different subtypes: 5-
HTR2A, 5-HTR2B, and 5-HTR2C [7]. The 5-HTR3 is a ligand-
gated cation channel triggering depolarization of the plasma
membrane through activation of Na
+ and K
+ fluxes [8]. The 5-
HTR4 receptor has two splice variants (5-HTR4a and 5-HTR4b)
[9]. The heptahelical 5-HTR5 subtype is less characterized [10]. 5-
HTR6 and 5-HTR7 are linked to Gs protein–mediated stimulation
of adenylyl cyclase [11,12].
Apart from its well-characterized function as a neurotransmit-
ter, 5-HT has been reported to be a potent immunoregulator:
Stimulation of serotoninergic receptors in human monocytes or
lung epithelial cells is associated with secretion of pro-inflamma-
tory cytokines [13,14]. Additionally, 5-HT plays a prominent role
in T-cell activation and in the interaction between T-cells and
dendritic cells [15,16]. Furthermore, 5-HT has chemotactic
activity for eosinophils and mast cells [17,18]. Consistently,
elevated serotonin levels have been detected in inflammatory
diseases such as bronchial asthma where a strong correlation
between disease severity and free plasma serotonin has been found
[19]. Methysergid, an antagonist at 5-HTR2 receptors, was able to
inhibit airway inflammation and remodelling in an animal model
of asthma [20].
Dendritic cells (DCs) are the most potent antigen presenting cells,
originating from hematopoietic stem cells [21,22]. Immature DCs
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6453are specialized in capturing and taking up antigens. DC maturation
can be induced by danger signals such as bacterial endotoxin
[23,24], or pro-inflammatory cytokines, e.g. TNF-a. During
maturation MHCII and co-stimulatory molecules on the cell
surfaceareup-regulated anddifferent cytokines and chemokines are
produced. Mature DCs migrate to secondary lymphoid organs
where they interact with naive T-cells, resulting in either Th1- or
Th2-dominated immune responses [21]. DCs also produce several
proinflammatory cytokines such as TNF-a, IL-1b, IL-6, and IL-8
profoundly affecting the outcome of inflammatory reactions
[16,25]. Furthermore DCs have been shown to be essential in the
pathogenesis of inflammatory processes such as bronchial asthma
[26–28]. Recently, we were able to demonstrate the functional
expression of 5-HTR on human DCs, linked to intracellular Ca
2+-
signalling and cytokine secretion [25]. However, the influence of 5-
HT on migration, production of chemokines such as CXCL10/IP-
10 or CCL22/MDC, and T-cell polarization capacity has not been
investigated yet.
In this study, we demonstrated that 5-HT is a chemoattractant
for immature but not LPS-matured DC in vitro and in vivo, via
activation of 5-HTR1B and 5HTR2 subtypes, while it modulate
the secretion of IL-6, CXCL10, CCL22 and the T-cell
polarization capacity of mature DC, via activation of 5-HTR4
and 5-HTR7 subtypes.
Materials and Methods
Reagents
5-Hydroxytryptamine (5-HT), N-Methyl-5-Hydroxytryptamine
(2Me5HT, 5-HTR3 agonist), R-(-)-DOI-hydrochloride (DOI, 5-
HTR2 agonist), Ketanserin (5-HT2 antagonist), and LPS were
obtained from Sigma-Aldrich (Deisenhofen, Germany). 5-Carbox-
amidotryptamine maleate (5-CT, 5-HTR1 agonist), BRL-54443
(5-HT1E/F agonist), 8-Hydroxy-DPAT-hydrobromide (8-HDPAT,
5-HTR7/1A agonist), GR 55562 (5-HT1B antagonist), Anpirtoline
hydrochloride (AnHCL, 5-HTR1B agonist), RS67333 hydrochlo-
ride (5-HT4 agonist), RS39604 hydrochloride (5-HT4 antagonist)
and SB-269970 (5-HT7 antagonist) hydrochloride were purchased
from Tocris (Bristol, UK).
Preparation of human DC
Peripheral mononuclear cells were separated from buffy coats
using a Ficoll gradient. After separation, the leukocyte-containing
pellet was resuspended in 2 ml PBS containing 0.15% EDTA and
0.5% BSA. Cells were separated with anti-CD14 mAb-coated
MicroBeads using Macs single use separation columns from
Miltenyi Biotec (Bergisch Gladbach, Germany). The CD14
+ cells
were cultured for 5 days in RPMI 1640 medium containing 10%
FCS, 1% glutamine, 50 IU/ml penicillin, 50 mg/ml streptomycin,
1,000 U/ml IL-4, and 10,000 U/ml GM-CSF (Promocell,
Heidelberg, Germany) at 37uC in an humidified atmosphere with
5% CO2. These cells were CD14
neg, CD1a
pos, CD80
low, CD83
low,
CD86
low, and .95% CD115
high and are also referred as
immature DC. Maturation of DC was induced by incubation for
24 h in the presence of 3 mg/ml lipopolysaccharide (LPS; Sigma-
Aldrich). Mature DC were .95% CD80
high, CD86
high CD83
high
and CD115
low. Monoclonal Abs and their respective isotype
controls were from Coulter-Immunotech, Krefeld, Germany.
Migration assay
Experimentswereperformed intriplicateusing48-wellTranswell
chambers(Nucleopore,Tu ¨bingen,Germany).Bufferorstimuliwere
added into the lower compartment wells. Thereafter a 10 mm
polycarbonate membrane with a pore size of 5 mm (Nuclepore) was
placed over the wells. DC (10
5 cells/well) were added to the upper
compartment and incubated at 37uC for 90 min in a humidified
atmosphere. After removing the cells from the upper side of the
membrane by wiping over a profiled rubber, migrated DC on the
lowerside ofthe membranewerefixedinmethanoland stainedwith
hematoxylin. Migrated DC were counted in 5 randomly chosen
high-power (x400) fields and a mean value for each sample was
calculated. The chemotactic index was calculated as the ratio
between DC migrated in the presence and in the absence of stimuli.
Cytokine assays
IL-10 and IL-12p70 were measured in DC supernatants by
ELISA using matched pair of mAbs from BD PharMingen (San
Diego, CA). Quantikine human TNF-a ELISA was from R&D
Systems (Minneapolis, USA). CXCL10 and CCL17 were
measured in DC supernatants by ELISA using matched pair of
mAbs and ELISA kit from BD PharMingen and R&D Systems,
respectively. Release of IFN-c and IL-5 from T cells was detected
using matched pairs of mAbs (BD PharMingen). Samples were
assayed in triplicate for each condition.
T cell differentiation assay
CD4
+ T lymphocytes were separated (.95% CD4
+ cells) from
the heavy density fraction (50–60%) of Ficoll gradients (Amersham-
Pharmacia Biotech) performed on PBMC, followed by immuno-
magnetic depletion using a mixture of anti-HLA-DR, anti-CD19
and anti-CD8 mAb conjugated beads (Dynal, Oslo, Norway).
Allogeneic naive T cells were purified (.95% CD45RA
+)b y
incubation of CD4
+ cells with anti-CD45RO mAb followed by a
goatanti-mouse Igcoupledtoimmunomagneticbeads,andthenco-
cultured (10
6 cells/well) with DC (5610
4 cells/well) in a 24-well
plate in 1640 RPMI medium supplemented with 5% human serum.
After 5d IFN-c, IL-5 and IL-13 release were determined by ELISA.
Animal studies
Mice. BALB/c mice (6–8 weeks old) were purchased from
Harlan (Zeist, The Netherlands). OVA-TCR transgenic mice
(DO11.10) on a BALB/c background were bred at the animal
facilities at the University Hospital Freiburg.
Effect of 5-HT on the T-cell priming capacity of DCs
Ova-specific naive T cells (1610
7) purified from DO11.10 TCR
transgenic mice were injected intravenously in the lateral tail vein of
BALB/c mice (day 0). On day 2, the mice received an i.t. injection
of 1610
6 OVA-pulsed DCs, 5-HT/OVA-pulsed DCs, or control
unpulsed DCs. On day 6, MLNs were collected and homogenized.
Forcytokine measurement,MLNcells were platedin round-bottom
96-well plates (1610
6 cells/ml in RPMI1640/5% FCS) and re-
stimulated with OVA (10 mg/ml) for 4 days. IL-4, IL-5, IL-13, and
IFN-c were assayed in supernatants by ELISA (R&D Systems,
Minneapolis, USA; eBioscience Inc., San Diego, CA).
Effect of 5-HT on DC migration
To address migration of lung DCs 80 mlo fF I T C - O V A( 1 0m g /
ml), with or without 5-HT (was administered intratracheally under
direct vision through the opening vocal cords using a 18-gauge
polyurethane catheter connected to the outlet of a micropipette as
previously described (4). Control mice received 80 mlo fP B S / D M S O .
At 24–36 h after injection, migrating DCs were enumerated in the
mediastinal LN as CD11c+MHCII+ cells carrying FITC+ material.
In all experiments, dead cells were excluded form analysis using
propidium iodide. Analysis was performed on a FacsCalibur flow
cytometer, using Cellquest and FlowJo software.
Serotonin and Dendritic Cells
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Experiments with human cells were reviewed and approved by
the ethics committee of the University hospital Freiburg. Animal
experiments were approved by the local animal ethics committee
(Regierungspra ¨sidium Freiburg) and performed according to the
respective guidelines.
Statistical analysis
For all experiments, the statistical significance of differences
between samples was calculated using the ANOVA, Bonferroni
comparison test. Differences were considered significant if p,0.05.
Results
5-HT induces migration of immature but not mature DCs
via activation of 5-HTR1 and 5HTR2 receptor subtypes
It has recently been reported that 5-HT is a potent chemoat-
tractant for human mast cells and eosinophils, via activation of 5-
HTR1 or 5HTR2 receptor subtypes respectively [17,18]. To
investigate the ability of 5-HT to induce migration of DCs, immature
and LPS-matured DCs were stimulated with increasing concentra-
tions of 5-HT. As shown in Figure 1A 5-HT elicited a typical dose-
dependent bell-shaped chemotactic response for immature DCs,
while it failed to induce migration in LPS-matured DCs.
To determine the 5-HTR-subtypes involved inthe 5-HT induced
migration,immatureDCwherestimulatedwith5-HT(1 mM)inthe
presence of the 5-HTR1B antagonist GR55562 (100 nM), 5-HTR2
antagonist ketanserinorvehicle. Both antagonistsalonewereable to
partially inhibit 5-HT mediated migration, while when applied in
combination they completely abolished this response (Fig. 1B),
suggesting the involvement of 5HTR1B and 5-HTR2A subtypes.
Stimulation with the 5-HTR1 agonist 5-CT or the 5-HTR2
agonist DOI also resulted in migration of immature DCs. This
response was blocked by pre-incubation with GR55562 or
ketanserin (Fig. 1C).
5-HT induces migration of DCs to mediastinal lymph
nodes
To test whether 5-HT is also a chemotaxin for DCs in vivo,
fluorescently labelled OVA was injected intratracheally together
with 5-HT or vehicle. The transport of the large molecule FITC-
OVA is an exclusive function of lung-derived DCs, being able to
transport this complex across the epithelial tight junction barrier.
The number of MHCII
+CD11c
+ DCs carrying fluorescent FITC-
OVA cargo was enumerated in the MLNs 1 day after instillation,
Figure 1. 5-HT induces migration of immature DCs. (A) DCs were
exposed to the indicated concentrations of 5-HT for 90 min at 37uCi na
Boyden chamber as described in material and methods. The
chemotactic index was calculated. Data are means6SEM (n=5). (B)
Cells were pre-treated with the 5-HTR1B antagonist G55562, 5-HTR2
antagonist ketanserin (both 100 nM) or vehicle. Migration in response
to 5-HT (1 mM) was determined as described above and the
chemotactic index was calculated as described above ([Fig. 1B]). Data
are means6SEM (n=5). (C) Cells were pre-treated with the 5-HTR1B
antagonist G 55562, the 5-HTR2 antagonist ketanserin (both 100 nM) or
vehicle. Migration in response to 5-HT, the 5-HTR2 agonist DOI (10 mM),
and the 5-HTR1 agonist 5-CT (10 mM) was determined and the
chemotactic index was calculated as described above ([Fig. 1C]). Data
are means6SEM (n=5)*p,0.05, **p,0.01, ***p,0.001. (D) Mice were
injected intratracheally with OVA-FITC (10 mg/ml) together with 5-HT
(100 mM) or vehicle. One day later, the presence of OVA-FITC carrying
CD11c
+MHCII
+ DCs in mediastinal lymph nodes was analyzed by flow
cytometry.
doi:10.1371/journal.pone.0006453.g001
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PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6453and, as shown in Figure 1D, 5-HT markedly increased the number
of DCs in mediastinal lymph nodes.
5-HT modulates cytokine and chemokine production in
mDCs
We previously reported that 5-HT can enhance the production
of the pro-inflammatory cytokines IL-8 and IL-1b via activation of
5-HTR3, 5-HTR4 and 5-HTR7 subtypes in human monocyte-
derived dendritic cells [25]. We therefore were interested if 5-HT
is also able to influence secretion of IL-6, IP-10, MDC IL-10 or
IL-12p70 in immature and mature DCs. Cells were stimulated for
24 h and cytokine content in the supernatants was analyzed by
ELISA.
Immature DCs produce high levels of CCL22/MDC and very
low levels of IP-10/CXCL10, whereas in LPS-matured DCs the
secretion of both CCL22 and CXCL10 is up-regulated (Fig. 2).
When DCs were treated with LPS in the presence of 5-HT, a dose
dependent inhibition of CXCL10 production was observed
(Fig. 2A), while the production of CCL22 was increased. In
addition 5-HT also enhanced the secretion of CCL22 in immature
DCs (Fig. 2B).
The proinflammatory cytokine IL-6 is involved in both acute
inflammation and chronic tissue remodelling. As shown in Figure 3,
5-HT, the 5-HTR3-agonist 2Me5-HT, the 5-HTR4 agonist RS
67333 and the 5-HTR7/1A agonist 8-HDPAT increased IL-6 release
of in maturing DCs.
IL-10 and IL-12p70 are cytokines playing a prominent role in T-
cell differentiation [29]. Added together with LPS, 5-HT dose
dependently inhibited the production of IL-12p70 (Fig. 4A),
whereas IL-10 release was increased (Fig. 5A). This effect was
mediated by 5-HTR4 and 5-HTR7 receptor subtypes, as preincu-
bation of mDC with a combination of the 5-HTR4 antagonist
RS39604 and the 5-HTR7 antagonist SB269970 completely
abolished 5-HT induced modulation of IL-10 and IL-12p70 release
(Fig. 4/5B). No significant effect of 5-HT on basal IL-10 and IL-
12p70 secretion in iDCs could be observed (Fig. 4/5A).
5-HT influences the T-cell polarizing capacity of mDCs
Starting from our observation that activation of 5-HTR4 and 5-
HTR7 subtypes inhibited the production of IL-12p70, which is an
important factor influencing the differentiation of Th1 cells, we
next analyzed the quality of primary T cell response induced by
DC matured in the presence of different concentration of 5-HT.
Naive CD4
+CD45RA
+ allogeneic T cells primed with mDC
exposed to various concentration of 5-HT during maturation
displayed an impaired Th1 and enhanced Th2 polarization, as
determined by the increased production of IL-13 and IL-5 as well
as down regulation of IFN-c (Fig. 6). T cells stimulated with 5-HT
pre-treated iDC showed an also higher IL-5 and IL-13 secretion
(Fig. 6A/B).
5-HT induces Th2-priming in vivo
In vivo relevance of Th2-priming induced by 5-HT was
investigated in an animal model: female BALB/c mice received a
cohortof naive OVA-TCR Tg (DO11.10) T cells intravenously. Two
Figure 2. 5-HT inhibits the release of IP 10/CXCL10 and
stimulates MDC/CCL22 secretion in DCs. Immature and mature
DCs were left untreated or were stimulated with the indicated
concentration of 5-HT for 24 h (A–B). CXCL10 and CCL22 release was
measured by ELISA. The results are expressed as mean pg/ml6SEM
(n=4).
doi:10.1371/journal.pone.0006453.g002
Figure 3. Stimulation of serotoninergic receptors induces
secretion of IL-6 in mature DCs. Mature DCs were stimulated with
the indicated concentrations of 5-HT or isotype receptor agonists.
Supernatants were collected 24 h after stimulation and IL-6 concentra-
tion was measured by ELISA. Results are given as mean 6 SEM (n = 4).
doi:10.1371/journal.pone.0006453.g003
Serotonin and Dendritic Cells
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OVA-pulsed DCs, serotonin-treated OVA-pulsed DCs, or control
unpulsed DCs. As shown in figure 6D, mediastinal lymph nodes cells
of mice receiving serotonin-pulsed DCs produced higher amounts of
IL-4, IL-5, and IL-13 whereas production of IFN-c was inhibited.
Discussion
5-HT is one of the major mediators secreted during platelet
aggregation or following cross-linking of IgE antibodies on mast cells
[2,3]. Moreover, increasing evidences u g g e s t st h a t5 - H Ti si n v o l v e di n
the pathogenesis of allergic asthma, as elevated 5-HT levels have been
detected in blood and sputum samples of asthmatic patients compared
to healthy individuals [19]. Additionally, a negative correlation
between serum 5-HT levels and pulmonary function tests was found
in asthmatics [19]. Treatment of asthmatic patients with the 5-HT
reuptake accelerator tianeptine has been shown to lead to a clinical
improvement [30–32]. Recently, the functional expression of different
5-HTR subtypes on human monocyte-derived dendritic cells has been
reported [25]. In this study, we provide additional evidence that 5-HT
is a powerful modulator of dendritic cell function thus being able to
enhance allergic airway inflammation.
Figure 4. 5-HT modulates IL-12p70 production of human
monocyte-derived DCs. (A) Immature and mature DCs were
stimulated with the indicated concentration of 5-HT concentrations.
Supernatants were collected 24 h after stimulation and cytokine
content was measured by ELISA. Results are given as mean6SEM
(n=4). (B) Mature DCs were preincubated with 10
27 M of the selective
5-HTR4 antagonist RS39604 or the 5-HTR7 antagonist SB269970 30 min
prior to stimulation with 5-HT. 24 hours later production of IL-12p70
was measured by ELISA. Data are means6SE (n=5)*p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0006453.g004
Figure 5. 5-HT modulates IL-10 production of human mono-
cyte-derived DCs. (A) Immature and mature DC were stimulated with
the indicated concentration of 5-HT concentrations. Supernatants were
collected 24 h after stimulation and IL-10 content measured by ELISA.
R e s u l t sa r eg i v e na sm e a n 6SEM (n=4). (B) Mature DCs were
preincubated with 10
27 M of the selective5-HTR4 antagonist RS39604
or the 5-HTR7 antagonist SB269970 30 min prior to stimulation with 5-
HT. 24 hours later production of IL-10 was measured by ELISA. Data are
means6SE (n=5)*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0006453.g005
Serotonin and Dendritic Cells
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direct chemo-attractant for immature but not mature human DCs.
By using the 5-HTR1B antagonist GR 55562 and the 5-HTR2A
antagonist ketanserin we could show that both receptor subtypes
are involved in the 5-HT-induced migration of iDC. Interestingly,
5-HT has been reported to induce migration of human eosinophils
[17] and human aortic smooth muscle cells [33] by selective
activation of 5-HTR2A-subtypes, while others reported that the
receptor subtypes 5HTR1B and 5HTR1A were involved in 5-HT-
mediated chemotaxis of human aortic endothelial cells [34] and
mast cells [18]. However, during maturation DCs loose the ability
to migrate in response to 5-HT. Similar to other well-described
mediators of allergic inflammation such as histamine or nucleo-
tides this might be a prerequisite for the departure of DCs to
secondary lymphoid organs [35,36]. As shown by the increased
number of DCs in mediastinal lymph nodes following adminis-
tration of 5-HT, these findings are relevant in vivo. Therefore, 5-
HT release during allergen challenge might be important for the
recruitment of DCs to the site of inflammation.
Previous studies were able to demonstrate that 5-HT is a potent
regulator of cytokine secretion in different kinds of cells. Here we
show that 5-HT increase production of the pro-inflammatory
cytokine IL-6 in mature DCs via 5-HTR3, 5-HTR4 and 5-HTR7
subtypes. These findings are in accordance with previous studies
conducted with human monocytes [14] and airway epithelial cells
[13]. Additionally, via activation of 5-HTR4 and 5-HTR7
receptors, 5-HT up-regulated production of IL-10 by human
LPS-matured DCs. Similar effects of 5-HT on IL-10 release have
been observed in human LPS-treated monocytes [14], whereas no
effect on IL-10 production has been seen in human peripheral
blood mononuclear cells treated with 5-HT [37]. IL-12p70 is
known as a cytokine favouring Th1-polarisation [38]. According
to previous data of our group, IL-12p70 secretion was dose-
dependently inhibited by 5-HT [25].
DCs are known to produce different chemokines thereby
regulating the traffic of Th1 and Th2 cells into inflamed tissue
[39]. Besides its influence on cytokine secretion, stimulation with
5-HT up-regulated production of MDC/CCL22 in both imma-
ture and mature DCs, while secretion of CXCL10 was inhibited in
mature DCs. 5-HT is known to increase intracellular cAMP levels
via activation of 5-HTR4 and 5-HTR7 receptors [25]. In
accordance, cAMP-elevating agents, such as histamine or
prostaglandins have similar effects on CCL22 and CXCL10
secretion [40,41]. CCL22 preferentially attracts Th2 cells, while
CXCL10 is a key chemokine for the recruitment of Th1 cells, it
can be assumed that DCs exposed to 5-HT (e.g. released during
allergen challenge) preferably attract Th2 cells leading to a Th2-
dominated microenvironment [42,43].
Recently Katoh et al reported that 5-HT reduced the capacity
of immature DCs to activate allogeneic T-cells [44]. However, the
effect of 5-HT on mature DCs has not been investigated in this
Figure 6. 5-HT modulates T-cell priming capacity of human
monocyte-derived DCs. Immature DCs were left untreated or
stimulated with 5-HT, or were induced to undergo maturation with
LPS in the absence or the presence of indicated concentration of 5-HT
for 24 h. DCs were then used to prime purified allogeneic
CD4+CD45RA+ naive T cells. After 5 days, supernatants from T cells
were evaluated for the secretion of IL-5 (A), IL-13 (B) and IFN-c (C).
Results are expressed as mean pg/ml6SD (n=3). *p,0.05 between
cytokines secreted by T cells stimulated with DC treated or not with 5-
HT. (D) Naive mice received 10610
6 DO11.10 CD4
+ T-cells intravenously
on day-2. On day 0 mice were instilled intratracheally with 10
6 OVA-
pulsed, OVA-pulsed 5-HT treated DCs, or unpulsed DCs. On day4
mediastinal lymph node cells were collected and cultured for 4 days.
Four days later, supernatants were harvested and analyzed for the
presence of IL-4, IL-5, IL-13, and IFN-c using commercially available
ELISAs .
doi:10.1371/journal.pone.0006453.g006
Serotonin and Dendritic Cells
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the authors suggest the involvement of 5-HTR1E and 5-HTR7 in
this cellular response. In contrast, we could show here, that DCs
matured in the presence of 5-HT induced a Th2-polarisation in
naive CD4
+CD45RA
+ T-cells, as demonstrated by downregula-
tion of IFN-y and upregulation of IL-5/IL-13 production
consistent with the capacity of 5-HT to increase IL-10 and to
inhibit IL-12p70 secretion in maturing DCs. This in vitro
observation could be confirmed in an animal model, where 5-
HT favoured the outcome of a Th2-response in mediastinal lymph
nodes.
DCs are essential for the induction and maintenance of allergic
diseases such as bronchial asthma [28,45]. Here we provide
additional evidence that 5-HT can influence human dendritic cell
function in a pro-asthmatic way. 5-HT which is released following
allergen challenge has chemotactic activity on immature but not
mature DCs leading to accumulation of DCs at the site of
inflammation. Under the influence of 5-HT DCs secrete larger
amounts of IL-6, a cytokine important for airway-remodelling and
mucus hypersecretion [46,47]. By increasing IL-10 and inhibiting
IL-12p70 secretion 5-HT influences the T-cell priming capacity of
DCs favouring the outcome of a Th2-response [22]. Additionally,
up-regulation of CCL22 and down-regulation of CXCL10 release
by 5-HT might lead to selective accumulation of Th2-cells into
inflamed tissue [43].
In conclusion our data provide further evidence that 5-HT is
involved in the pathogenesis of allergic diseases. Therefore, the use
of specific 5-HTR antagonists targeting the function of DCs, might
be a new therapeutic option in allergy treatment.
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